Abstract
Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Current Pharmaceutical Design
Title:CNS Transporters and Drug Delivery in Epilepsy
Volume: 20 Issue: 10
Author(s): Heidrun Potschka and Hiram Luna-Munguia
Affiliation:
Keywords: Seizure, blood-brain barrier, transporter, drug resistance, p-glycoprotein.
Abstract: Unfortunately, antiepileptic drug therapy fails to control seizure activity in a relevant percentage of epilepsy patients. Epidemiological data as well as findings in human epileptic tissue and in rodent models indicate that drug resistance is a multi-factorial phenomenon with various factors contributing to therapeutic failure. Enhanced efflux transport of antiepileptic drugs as a consequence of seizure-associated up-regulation of transporters such as P-glycoprotein constitutes one factor discussed in this context. Evidence exists that expression rates of P-glycoprotein correlate with drug response in rodent models and in patients. Moreover, add-on of a Pglycoprotein modulator proved to be efficacious in a rat model of drug-resistant epilepsy.
Further proof is obviously needed regarding the relative functional relevance of blood-brain barrier efflux for antiepileptic drug efficacy in epilepsy patients. Ongoing studies with positron emission tomography using transporter substrate radiotracers might provide further information. However, these studies also face major challenges considering the complexity of various factors affecting the kinetics of radiotracers in central nervous system pathologies.
Export Options
About this article
Cite this article as:
Potschka Heidrun and Luna-Munguia Hiram, CNS Transporters and Drug Delivery in Epilepsy, Current Pharmaceutical Design 2014; 20 (10) . https://dx.doi.org/10.2174/13816128113199990461
DOI https://dx.doi.org/10.2174/13816128113199990461 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Restless Legs Syndrome in Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Local Cerebral Blood Flow is Preserved in Sepsis
Current Neurovascular Research Targeting of Low-Molecular Weight Drugs to Mammalian Mitochondria
Drug Design Reviews - Online (Discontinued) Homocysteine in Neurological Disease: A Marker or a Cause?
CNS & Neurological Disorders - Drug Targets Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?
Current Drug Safety MicroRNA-451 Aggravates Kainic Acid-induced Seizure and Neuronal Apoptosis by Targeting GDNF
Current Neurovascular Research An Emerging Strategy for Cancer Treatment Targeting Aberrant Glycogen Synthase Kinase 3β
Anti-Cancer Agents in Medicinal Chemistry Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Serpin Regulation of Fibrinolytic System: Implications for Therapeutic Applications in Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry α-Substituted Lactams and Acetamides: Ion Channel Modulators that Show Promise in Treating Drug-resistant Epilepsy
Central Nervous System Agents in Medicinal Chemistry p38 MAP Kinase Inhibitors as Potential Therapeutic Drugs for Neural Diseases
Central Nervous System Agents in Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Transdermal Drug Delivery: A Step towards Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery Drug Targets of Migraine and Neuropathy: Treatment of Hyperexcitability
CNS & Neurological Disorders - Drug Targets Development of a Registry for Down Syndrome in the Gulf Area of the Middle East
Applied Clinical Research, Clinical Trials and Regulatory Affairs synthesis and Structure-Activity Relationships of 2,3-Benzodiazepines as AMPA Receptor Antagonists
Mini-Reviews in Medicinal Chemistry Preclinical Analyses of the Therapeutic Potential of Allopregnanolone to Promote Neurogenesis In Vitro and In Vivo in Transgenic Mouse Model of Alzheimers Disease
Current Alzheimer Research Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis
Current Pharmaceutical Design The Regulation of Brain Nucleoside Utilization
Current Metabolomics